LITS
Lite Strategy, Inc.
Healthcare — Biotechnology
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
None
$1.38
+$0.05 (+4.17%)
Price History
52-Week Range
Sign in to add LITS to a watchlist or set price alerts.
Fundamentals
| Market Cap | $33.00M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-2.08 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -159.26% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | Sep 29, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 70.9 |
| Beta | 0.04 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $9.00 |
| 52-Week Low | $0.69 |
| 50-Day Avg | $1.01 |
| 200-Day Avg | $1.46 |
| Avg Volume | 398.4K |
| Volume | 94.8K |
Performance Analysis
NEUTRALLITS presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($0.69), which could present a value opportunity.
-
RSI at 70.9 indicates overbought conditions — a pullback may be due.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:18 UTC
Back to Screener Export Report